You are here

Article Text

Article menu

Download PDFPDF

Correspondence
Immune checkpoint inhibitor rechallenge in patients with immune-related myositis
Free
  1. Julie Delyon1,2,3,
  2. Florence Brunet-Possenti3,4,
  3. Sarah Leonard-Louis5,6,
  4. Dimitri Arangalage3,7,8,
  5. Mathilde Baudet9,
  6. Barouyr Baroudjian1,
  7. Celeste Lebbe1,2,3,
  8. Baptiste Hervier6,10,11
  9. on behalf of the PATIO Group
  1. 1 Department of Dermatology, APHP Saint Louis Hospital, Paris, France
  2. 2 INSERM U976, Paris, France
  3. 3 Paris Diderot, Sorbonne Paris Cité University, Paris, France
  4. 4 Department of Dermatology, APHP Bichat Hospital; Paris VII Diderot, Sorbonne Paris Cité University, Paris, France
  5. 5 Department of Neurology and Neuropathology, APHP Pitié-Salpêtrière Hospital, Paris, France
  6. 6 UPMC, Médecine Sorbonne Université, Paris, France
  7. 7 Cardiology Department, APHP Bichat Hospital, Paris, France
  8. 8 INSERM U1148, Paris, France
  9. 9 Department of Cardiology, APHP Saint Louis Hospital, Paris, France
  10. 10 Department of Internal Medicine, APHP Pitié-Salpêtrière Hospital, Paris, France
  11. 11 INSERM U1135-CIMI, Paris, France
  1. Correspondence to Dr Julie Delyon, Dermatology, APHP Saint Louis Hospital, Paris 75475, France; julie.delyon{at}aphp.fr

https://doi.org/10.1136/annrheumdis-2018-214336

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Therapeutic management of many cancers has been revolutionised by the development of immune checkpoint inhibitors (ICI) targeting antiprogrammed death 1 (PD-1)/ligand 1 (PDL1) and anticytotoxic T-lymphocyte antigen 4 leading to durable responses.1 ICIs however can induce several immune-related adverse events (irAE) including musculoskeletal irAEs.2 Among them, ICI-related myositis can be severe and sometimes life threatening.3 4 The current management includes permanent discontinuation of ICIs and steroid treatment. To date, very little is known about the risk of irAE recurrence in case of ICI rechallenge,5 6 especially in myositis for which no case of rechallenge has yet been reported. Through two cases, we report the safety of resuming anti-PD-1/PDL1 in patients …

    View Full Text